UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

Cell communication and signaling, 2022-01, Vol.20 (1), p.4-4, Article 4

2022

Volltextzugriff (PDF)

Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models

NPJ breast cancer, 2024-06, Vol.10 (1), p.40-15

2024

Volltextzugriff (PDF)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Journal of cancer research and clinical oncology, 2020-03, Vol.146 (3), p.605-619

2020

Volltextzugriff (PDF)

Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells

BMC cancer, 2017-03, Vol.17 (1), p.199-199, Article 199

2017

Volltextzugriff (PDF)

A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity

Oncotarget, 2016-11, Vol.7 (48), p.78577-78590

2016

Volltextzugriff (PDF)

Advantages and application of label-free detection assays in drug screening

Expert opinion on drug discovery, 2008-08, Vol.3 (8), p.891-901

2008

Volltextzugriff (PDF)

Abstract 3198: Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3198-3198

2020

Volltextzugriff (PDF)

Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.149-149

2023

Volltextzugriff (PDF)

Abstract 367: Sub-group of ovarian cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.367-367

2021

Volltextzugriff (PDF)

Validation of an optical microplate label-free platform in the screening of chemical libraries for direct binding to a nuclear receptor

Assay and drug development technologies, 2011-10, Vol.9 (5), p.532-548

2011

Volltextzugriff (PDF)

Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib

Cancers, 2024-10, Vol.16 (20), p.3520

2024

Volltextzugriff (PDF)

Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway

Molecular oncology, 2024-08

2024

Volltextzugriff (PDF)

Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway

Molecular oncology, 2024-08

2024

Volltextzugriff (PDF)

Test measuring signaling activity in live patient tumor cells to identify PI3KCA WT patients who may benefit from PI3K inhibitors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e13000-e13000

2020

Volltextzugriff (PDF)

Test identifies ovarian cancer patients with hyperactive c-Met and ErbB signaling tumors who may benefit from c-Met and pan-HER combination therapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e18038-e18038

2020

Volltextzugriff (PDF)

Abstract 342: Sub-group of HER2-negative breast cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.342-342

2021

Volltextzugriff (PDF)

Abstract P1-09-07: Sub-group of PIK3CA WT breast cancer patients have hyperactive S1P signaling tumor cells responsive to PIK3-inhibitors: Functional signaling profile test identifies new patient group who may benefit from PIK3-targeted therapies

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-09-07

2020

Volltextzugriff (PDF)

Abstract 4928: Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4928-4928

2023

Volltextzugriff (PDF)

Live tumor cell functional analysis and a xenograft model find co-activated c-Met and ErbB signaling in HER2-negative breast cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e24292-e24292

2018

Volltextzugriff (PDF)

Abstract PO1-24-04: Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO1-24-04-PO1-24-04

2024

Volltextzugriff (PDF)

A Model of the Iron Responsive Element RNA Hairpin Loop Structure Determined from NMR and Thermodynamic Data

Biochemistry (Easton), 1996-10, Vol.35 (42), p.13586-13596

1996

Volltextzugriff (PDF)

Measuring functional HER2-driven signaling status ex vivo to predict response to HER2 therapy: Results from a mouse breast tumor xenograft study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e23203-e23203

2017

Volltextzugriff (PDF)

Microplate-based, label-free detection of biomolecular interactions: applications in proteomics

Expert review of proteomics, 2006-06, Vol.3 (3), p.271-281

2006

Volltextzugriff (PDF)

Thermodynamics of RNA Folding in a Conserved Ribosomal RNA Domain

Journal of molecular biology, 1994-04, Vol.237 (5), p.560-576

1994

Volltextzugriff (PDF)

Profiling of signaling pathways in live tumor cells to assess drug mechanism of action: A method to predict drug efficacy in a patient

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e11583-e11583

2014

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(43)
Dissertationen
(1)

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells

A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity

Advantages and application of label-free detection assays in drug screening

Abstract 3198: Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status

Abstract 367: Sub-group of ovarian cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Validation of an optical microplate label-free platform in the screening of chemical libraries for direct binding to a nuclear receptor

Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib

Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway

Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway

Test measuring signaling activity in live patient tumor cells to identify PI3KCA WT patients who may benefit from PI3K inhibitors

Test identifies ovarian cancer patients with hyperactive c-Met and ErbB signaling tumors who may benefit from c-Met and pan-HER combination therapy

Abstract 342: Sub-group of HER2-negative breast cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Abstract P1-09-07: Sub-group of PIK3CA WT breast cancer patients have hyperactive S1P signaling tumor cells responsive to PIK3-inhibitors: Functional signaling profile test identifies new patient group who may benefit from PIK3-targeted therapies

Abstract 4928: Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status

Live tumor cell functional analysis and a xenograft model find co-activated c-Met and ErbB signaling in HER2-negative breast cancer

Abstract PO1-24-04: Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models

A Model of the Iron Responsive Element RNA Hairpin Loop Structure Determined from NMR and Thermodynamic Data

Measuring functional HER2-driven signaling status ex vivo to predict response to HER2 therapy: Results from a mouse breast tumor xenograft study

Microplate-based, label-free detection of biomolecular interactions: applications in proteomics

Thermodynamics of RNA Folding in a Conserved Ribosomal RNA Domain

Profiling of signaling pathways in live tumor cells to assess drug mechanism of action: A method to predict drug efficacy in a patient

Suchergebnisse filtern